### Biotage Company Overview August 2023

Dr. Olof Nord, Executive Vice President Business Development



HumanKind Unlimited

#### **Biotage** – A Global Life Science company





**Products sold in** more than +80 countries



**Direct sales** revenue 96%




Aftermarket 2023 split 64% / 36%

~ 4500 customers




**18 locations** globally & 6 **R&D** sites



#### Where we come from





#### Biotage's Strategic focus on Biologics & Advanced Therapeutics

Recent acquisitions strengthen our offering in the biologics and advanced therapeutic segment.

- Biologics outpaced small-molecule FDA-approvals for the first time in 2022\*
- Advanced therapeutics accounted for about half of the biologic FDA-approvals\*
- Oncology dominates the pipeline league tables and research into rare diseases has generated important new therapies\*\*.




solution at dbio



<u>\*Source: Nature, 9 Jan 2023</u> <u>\*\*Evaluate Pharma, Oct 2022</u> The Astrea Bioseparations transaction is conditional upon shareholder approval.

#### Biotage – A Global Life Science Tools & Service Provider Biotage



A quality **Workflow Modality, Tools & Service Provider** providing the shovels to the **Pharma, BioPharma** and **Diagnostic** Industry




 Biotage is providing the picks, screwdrivers and shovels to the Prospectors = Pharma, BioPharma and Diagnostic Industry

#### A Global Life Science Tools & Service Provider



Focus on High-Growth Blue Ocean niches in our Customers' Workflow with Buy-Partner-Build




## **Biotage** - Transforming mix towards dynamically growing Bioproduction & Bioprocessing






# Astrea Bisoseparations moves Biotage naturally into High-Growth Markets for Biomolecules









#### **HumanKind Unlimited**

